Improvement in postmastectomy radiotherapy for breast cancer in mainland China:comparison of survey in 2010 with 2004
HUI Zhou-guang, ZHANG Ye, ZHANG Jiang-hu,YU Zi-hao, LIU Xin-fan, JIN Jing, WANG Wei-hu, WANG Shu-lian, SONG Yong-wen, LIU Yue-ping, REN Hua, FANG Hui, LI Ye-xiong
Department of Radiation Oncology, Cancer Hospital (Insititute), Chinese Academy of Medical Sciences, Peking Union Medical College,Beijing 100021, China
Corresponding author:LI Ye-xiong, Email:yexiong3@yahoo.com.cn
Objective To assess the current practice of postmastectomy radiotherapy (PMRT) in mainland China and to evaluate the improvement in the past six years. Methods A questionnaire on the indications and techniques for PMRT for breast cancer was delivered to all radiotherapy centers of mainland China in 2010 survey, and the results were analyzed and compared with those in 2004 survey. The Fisher′s exact test was used. Results Compared to 29.4%(210/275) in 2004, 396 of the 952(41.6%) surveyed centers had performed PMRT. The median interval between surgery and PMRT was increased from 6 weeks to 12 weeks during the past 6 years. Adjuvant chemotherapy followed by PMRT was the most common combination in 73.5% of the responding centers in 2010 other than"Sandwich"(71.7%) sequence of chemotherapy and PMRT in 2004. PMRT was only performed for T3 or Stage Ⅲ tumors and/or ≥ 4 positive lymph nodes (LN+) in 7.1% centers in 2004 and in 29.5% centers in 2010 surveys, respectively. The use of PMRT for T1-2N0 breast cancer, T1-2N0 with tumors located in the center or inner quadrant, and stage T1-T2 and one to three LN+ was decreased from 11.9%, 63.8%, and 87.6% in 2004 to 1.5%, 19.7%, and 62.1% in 2010, respectively (all P=0.000). The chest wall and the supraclavicular region were the most common radiation targets, which were used in 97.0% and 97.0% in 2010, similar to 97.1% and 96.2% in 2004.Irradiation to the inner mammary area and axillary fossa decreased from 85.2% and 74.8% in 2004 to 39.1% and 50.5% in 2010.The boost to the chest wall was more based on the scar,increasing from 9.0% in 2004 to 75.0% in 2010. Conclusions There are a high level of compliance of the practices with current guideline and continuing improvement of PMRT for breast cancer in mainland China. But it needs further improvement.
HUI Zhou-guang,ZHANG Ye,ZHANG Jiang-hu et al. Improvement in postmastectomy radiotherapy for breast cancer in mainland China:comparison of survey in 2010 with 2004[J]. Chinese Journal of Radiation Oncology, 2012, 21(4): 352-356.
[1] Zhang BN, Shao ZM, Qiao XM, et al. A prospective multicenter clinical trial of breast conserving therapy for early breast cancer in China. Chin J Oncol,2005,27:680-684. [2] Early breast cancer trialists′ collaborative group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:an overview of the randomised trials. Lancet,2005,366:2087-2106. [3] Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy:clinical practice guidelines of the American society of clinical oncology. J Clin Oncol,2001,19:1539-1569. [4] Hui ZG, Li YX, Yu ZH, et al. Survey on use of postmastectomy radiotherapy for breast cancer in China. Int J Radiat Oncol Biol Phys,2006,66:1135-1142. [5] Ceilley E, Jagsi R, Goldberg S, et al. Radiotherapy for invasive breast cancer in north America and Europe:results of a survey. Int J Radiat Oncol Biol Phys,2005,61:365-373. [6] Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol,1998,16:2672-2685. [7] Hortobagyi GN, Singletary SE, Strom EA. Locally advanced breast cancer//Harris JR, Lippman ME, Morrow M, et al. Diseases of the breast. Philadelphia:Lippincott Williams& Wilkins,2004. [8] Huang J, Barbera L, Brouwers M, et al. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol,2004,21:555-563. [9] Rutqvist LE, Rose C, Cavallin-Stahl E. A systematic overview of radiation therapy effects in breast cancer. Acta Oncol,2004,42:532-545. [10] Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish breast cancer cooperative group 82b trial. N Engl J Med,1997,337:949-955. [11] Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen. Danish breast cancer cooperative group DBCG 82c trial. N Engl J Med,1999,353:1641-1648. [12] Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy:20-year results of the British Columbia randomized trial. J Natl Cancer Inst,2005,97:116-126. [13] Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in internation consensus reports? A subgroup analysis of the DBCG 82b & c randomized trials. Radiat Onocl,2007,82:247-253. [14] Recht A, Gray R, Davidson NE, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation:experience of the eastern cooperative oncology group. J Clin Oncol,1999,17:1689-1700. [15] Goldhirsch A, Gelber RD, Castiglione M. Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women:patterns and prognoses. J Clin Oncol,1988,6:89-97. [16] Buzdar A, McNeese MD, Hortobagyi GN, et al. Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer? Cancer,1990,65:394-399. [17] Taghian A, Jeong JH, Mamounas E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy:results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol,2004,22:4247-4254. [18] Metz JM, Schultz DJ, Fox K, et al. Long-term outcome after postmastectomy radiation therapy for breast cancer patients at high risk for local-regional recurrence. Cancer J Sci Am,1999,5:77-83. [19] Gez E, Ashaf N, Bar-Deroma R, et al. Postmastectomy electron-beam chest wall irradiation in women with breast cancer. Int J Radiat Oncol Biol Phys,2004,60:1190-1194. [20] Tieu MT, Graham P, Bioeth C, et al. The effect of adjuvant postmastecomty radiotherapy bolus technique on local recurrence. Int J Radiat Oncol Biol Phys,2011,81:165-171. [21] Sakorafas GH, Peros G, Cataliotti L, et al. Lymphedema following axillary lymph node dissection for breast cancer. Surg Oncol,2006,15:153-165. [22] Mignano JE, Zahurak ML, Chakravarthy A, et al. Significance of axillary lymph node extranodal soft tissue extension and indications for postmastectomy irradiation. Cancer,1999,86:1258-1262. [23] Obedian E, Haffty BG. Internal mammary nodal irradiation in conservatively-managed breast cancer patients:is there a benefit? Int J Radiat Oncol Biol Phys,1999,44:997-1003.